Single intracavernous injection of autologous adipose-derived stem cells versus a single high dose of Platelet Rich Plasma to improve erectile dysfunction: A comparative study

Single intracavernous injection of autologous adipose-derived stem cells versus a single high dose of Platelet Rich Plasma to improve erectile dysfunction - SICIADSCVSSIPRPTED

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049397

Enrollment

Registered

2022-11-02

Start date

2020-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction

Interventions

Adipose mesenchymal Stem Cells (ADSC) Single dose Intracavernous injections Platelet rich plasma (PRP) Single dose Intracavernous injections

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: male with severe ED refractory to conventional therapies

Exclusion criteria

Exclusion criteria: male with mild to moderate ED

Design outcomes

Primary

Measure	Time frame
effectiveness of single high dose PRP intracavernous injection and single dose of Adipose mesenchymal Stem Cells (ADSC) in patients with severe ED.	—

Countries

Asia(except Japan)

Contacts

Public ContactMohamad Moussa

Al Zahraa Hospital, Stem Cell institute Urology

mohamadamoussa@hotmail.com009613964412

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026